Significance of platelet and monocyte activation for therapeutic immunoglobulin-induced thromboembolism

Salge-Bartels, Ursula; Heiden, M.; Groß, Nannette; Seitz, Rainer

doi:10.1016/j.thromres.2013.11.026

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pulmonary embolism , myocardial infarction and cerebrovascular accidents were found in patients receiving IVIG therapy with pathological findings of plasma expansion and increased viscosity . Moreover, platelet activation , procoagulant activity , anaphylaxis in IgA‐deficient recipients and hepatitis C virus transmission were also reported. However, the incidence of IVIG‐induced thrombosis was reported to average from 3 to 13% , but the proposed mechanism seems to be irrelevant to the aggregate .…”

Section: Discussionmentioning

confidence: 97%

Acute pulmonary embolism caused by highly aggregated intravenous immunoglobulin

Hou

Shen

et al. 2015

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Acute pulmonary embolism caused by highly aggregated intravenous immunoglobulin

Hou

Shen

et al. 2015

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…81 It was also observed that high dose of IVIg infusion may impair platelet function as suggested in in vitro aggregometry studies. 62,82 A recent study 83 found that IVIg could influence platelet and monocyte activation via the ADP and TRAP-6elicited response. IVIg, particularly those associated with increased incidence of thromboembolic events, can impair FcγRII-dependent tissue factor expression in monocytes.…”

Section: Intravenous Immunoglobulinsmentioning

confidence: 99%

Thrombosis in Autoimmune Diseases: A Role for Immunosuppressive Treatments?

Silvestri

Scalera

Emmi

et al. 2016

Semin Thromb Hemost

View full text Add to dashboard Cite

Autoimmune diseases are not infrequently associated with arterial or venous thrombotic events. Chronic inflammation and immune system impairment are considered the main pathogenetic mechanisms. Some of the drugs used in the treatment of such diseases have been associated with an increased risk of thrombosis. On the contrary, their anti-inflammatory and immune modulator activity could correct some mechanisms leading to thrombosis. In this review, recent evidence available on this topic is examined. There is a lack of adequate studies, but available evidence suggests that glucocorticoids and high-dose immunoglobulins are associated with an increased incidence of venous thromboembolism. Although available data do not allow drawing definite conclusions and more data are needed from future studies and registries, physicians should be aware of these associations.

show abstract